RxDoctor Payments Data

David Rahni, MD

Gastroenterology · West Orange, NJNPI 1447571096

Payments from drug & device makers

$14,130in general payments, 2019–2025

Across 1,059 payments — averaging $13.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$1K
  • Boston Scientific$909
  • Takeda Pharmaceuticals U.S.A., Inc.$657
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$14,070100%
  • Education$600%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,130 in reported general payments places this provider in the 85th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$141,349
Medicare patients
537
Services billed
1,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$279,852
CreonLipase/Protease/Amylase26$166,417
XifaxanRifaximin39$113,328
RinvoqUpadacitinib12$94,406
LinzessLinaclotide82$63,228
TrulancePlecanatide52$46,070
Dexlansoprazole DrDexlansoprazole33$18,691
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C72$9,940
Mesalamine21$9,562
Alosetron Hcl11$7,543
Ursodiol35$7,262
Sucralfate17$5,954
Pantoprazole Sodium322$5,191
Famotidine45$5,164
SutabSod Sulf/Pot Chloride/Mag Sulf21$3,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Rinvoq, Linzess$2,054$324,050120 claims
Johnson & JohnsonStelara$1,157$279,85212 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$3,135$169,338163 claims
Braintree Laboratories, Inc.Sutab$242$3,34821 claims
Ferring Pharmaceuticals Inc.Clenpiq$175$2,95417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →